Idiopathic Hypersomnia Treatment Market
- 2026 年市場規模
- USD 394.7 Mn
- 2033 年預估規模
- USD 709.6 Mn
- 年複合成長率 CAGR
- 8.7%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Idiopathic Hypersomnia Treatment Market, By Drug Class (Stimulant Medications, Non-stimulant wake-promoting Medications,Sodium Oxybate), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Idiopathic hypersomnia is a rare sleep disease that causes a person to be excessively sleepy during the day even after a good or prolonged night's sleep. It also causes difficulty in waking up among patients after a night sleep or a nap. Moreover, narcolepsy and idiopathic hypersomnia are both types of hypersomnia but there are differences, which can be observed by diagnostic tests such as Polysomnography (PSG) that lies in the number of sleep-onset REM periods (SOREMPs). Patients with narcolepsy have two or more SOREMPs from Polysomnography (PSG) and Multiple Sleep Latency Test (MSLT) results, whereas patients with idiopathic hypersomnia do not. There are symptomatic treatment such as increase wakefullness options available for idiopathic hypersomnia, while there is not a single approved drugs for this disease.
Market Dynamics
Rising number of pipeline products and increasing cases of lifestyle diseases are some of the major factors responsible for growth of the global idiopathic hypersomnia treatment Market. For instance, in October 2020, Jazz Pharmaceuticals announced positive topline results from a phase 3 study evaluating Xywav (calcium, magnesium, potassium, and sodium oxybates) for the treatment of idiopathic hypersomnia that showed that the trial met the primary point (measured Epworth Sleepiness Scale (ESS) and key secondary end points [Patient Global Impression of Change (PGIc) and Idiopathic Hypersomnia Severity Scale (IHSS)].
Key features of the study
• This report provides in-depth analysis of the global idiopathic hypersomnia treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global idiopathic hypersomnia treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Inc., BIOPROJET, Avadel Pharmaceuticals, Plc. GlaxoSmithKline plc, Pfizer Inc., Theranexus, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare LLC, and Merck & Co. Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global idiopathic hypersomnia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global idiopathic hypersomnia treatment Market
Idiopathic Hypersomnia Treatment Market Segmentation
• By Drug Class
o Stimulant Medications
o Non-stimulant wake-promoting Medications
o Sodium Oxybate
• By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Idiopathic Hypersomnia Treatment Market, By Region
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Takeda Pharmaceutical Company Limited
o Teva Pharmaceutical Industries Ltd.
o Jazz Pharmaceuticals, Inc.
o BIOPROJET
o Avadel Pharmaceuticals plc
o GlaxoSmithKline plc
o Pfizer Inc.
o Theranexus
o Fisher & Paykel Healthcare Limited
o Drive DeVilbiss Healthcare LLC
o Merck & Co., Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o CKD Stages Treatment Options
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Pipeline Analysis
o Market Trends
o Recent Product Launch/Approvals
o Cost of Treatment
o Regulatory Scenario
o PEST Analysis
o Mergers, Acquisitions, and Partnerships
o Epidemiology
o Reimbursement Scenario (Medicare Part D Spending)
4. Global Idiopathic Hypersomnia Treatment Market, By Drug Class, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026, and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Stimulant Medications
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Non-stimulant wake-promoting Medications
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Sodium Oxybate
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
5. Global Idiopathic Hypersomnia Treatment Market, By Distribution Channel, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026, and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospital Pharmacies
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Online Pharmacies
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Retail Pharmacies
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
6. Global Idiopathic Hypersomnia Treatment Market, By Region, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026, and 2033 (%)
Y-o-Y Growth Analysis, For Region, 2021 - 2033
o North America
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o U.S.
o Canada
o Latin America
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o South Africa
o Central Africa
o North Africa
7. Competitive Landscape
o Heat Map Analysis
o Company Profiles
Takeda Pharmaceutical Company Limited
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Teva Pharmaceutical Industries Ltd.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Jazz Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
BIOPROJET
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Avadel Pharmaceuticals, Plc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
GlaxoSmithKline plc,
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Pfizer Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Theranexus
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Fisher & Paykel Healthcare Limited
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Innovation Pharmaceuticals Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Drive DeVilbiss Healthcare LLC
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Merck & Co. Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
8. Section
o Research Methodology
o About us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們